Answers are grounded in this paper and cite their sources.
Among the various expression hosts available for the heterologous production of recombinant proteins, insect systems combine eukaryotic protein-processing capacity, genetic tractability, and scalable cultivation. This review provides an overview of recombinant protein expression and manufacturing technologies based on Drosophila melanogaster, focusing on the established Schneider 2 cell system and the emerging transgenic whole-fly platform. By systematically examining stable expression, secretory production, serum-free suspension culture, bioreactor scale-up, downstream purification, and quality control, we demonstrate that Schneider 2 cells have developed into a relatively mature production platform. We further emphasize that glycosylation is a major determinant of product suitability and a central target of host engineering. In the whole-fly platform, site-specific transgenesis together with tissue-specific or inducible regulation enables protein expression to be coordinated with tissue function and developmental stage, providing a foundation for establishing a whole-fly production platform. In addition, evaluation of clinical-stage antigens produced in Schneider 2 cells and recent whole-fly production cases defines the current maturity of Drosophila-based recombinant protein process development and platform construction and identifies the associated developmental challenges. Overall, although Drosophila-based recombinant protein expression has not yet achieved commercial production, relatively mature and operational process workflows have been established. Future efforts should therefore focus on developing targeted production platforms for product areas in which Drosophila has advantages, rather than pursuing a universal platform applicable to all recombinant proteins.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: